---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-045341"
form_type: "8-K"
ticker: "MGRX"
cik: "0001938046"
company_name: "MANGOCEUTICALS, INC."
filed_at: "2026-10-01T19:50:43+00:00"
generated_at: "2026-10-12T14:20:48.738751+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Mangoceuticals' MangoRx IP sells 25% stake for $2.5M; $1.75M received, no MGRX shares issued

## Summary
- Two accredited investors agreed to buy an aggregate 25% membership interest in subsidiary MangoRx IP Holdings for $2.5M; $1.75M (17.5% post-transaction) already received.
- First investor paid $500,000 upfront in cash or Tether (USDT) plus $750,000 within 60 days; remaining 7.5% costs $750,000, due by November 28, 2026.
- No MGRX common stock, warrants or other parent securities issued; CEO Jacob Cohen says the deal preserves the public capitalization structure.
- MangoRx IP owns the MGX-0024 antiviral portfolio, led by U.S. Patent No. 11,517,523, with granted or pending patents in the EU, Canada, China, India, Australia and Japan.
- Company cites Fortune Business Insights 2025 markets of ~$34.8B for global oral care and ~$39.8B for feed additives as potential applications.

## SEC filing metadata
- accession: 0001493152-26-045341
- form_type: 8-K
- ticker: MGRX
- cik: 0001938046
- company_name: MANGOCEUTICALS, INC.
- filed_at: 2026-10-01T19:50:43+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 2.01, 9.01, 3.02, 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1938046/000149315226045341/0001493152-26-045341-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1938046/000149315226045341/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-045341
- JSON: https://secwatch.observer/filing/0001493152-26-045341.json
- Plain text: https://secwatch.observer/filing/0001493152-26-045341.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.